Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Accuryn Medical
Hayward, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Accuryn Medical's Accuryn Monitoring System is FDA-cleared, CE-marked, and is commercialized in hospitals. Clinical studies show the system can detect AKI 33 hours earlier than standard lab tests. The platform has shipped nearly 100,000 catheters and is in use at more than 70 hospitals. Its AKI prediction algorithm received FDA Breakthrough Device Designation in 2022, and clinical evidence supports earlier intervention and improved outcomes for AKI patients.[2][3]
- Therapeutic areas
- NephrologyGastroenterologyOther
- Modalities
- DeviceArtificial intelligence
- Industry
- Physiological Monitoring
Beyond the preview
Go deeper on Accuryn Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accuryn Medical.